Recent approval of the RNAi based drug, Onpattro (developed by Alnylam Pharmaceuticals), for the treatment of hATTR amyloidosis has renewed the interest of various stakeholders in this upcoming field of research. Further, in late 2019 Givlaari (developed by Alnylam Pharmaceuticals) was approved for the treatment of acute hepatic porphyria.
To request sample pages, please visit : https://www.rootsanalysis.com/reports/278/request-sample.html
During our research, we came across 175 drug candidates that are either approved or are in clinical / preclinical stage of development for the treatment of various diseases. Majority (36%) of the pipeline candidates are being developed to target various oncological disorders. It is worth highlighting that majority of these drug candidates (68%) are in early phases of development. Further, candidates that target infectious diseases and genetic disorders represent 11% and 6% of the pipeline, respectively. Other important therapeutic areas for which RNAi therapeutics are being developed include ophthalmic diseases (6%) and respiratory disorders (5%).
Amongst the type of RNA molecule, siRNA (73%) is the most popular molecule being used for drug development, primarily due to its high specificity for single mRNA target.Other key molecules being used for the development of RNAi therapeutics include miRNA (16%), shRNA (6%) and DNA (4%). Currently, about two third of the RNAi therapeutic pipeline is in early phases of development, indicating that this domain has significant opportunity in the mid-long term. Moreover, siRNA-based therapeutics are widely distributed across different phases of development; interestingly, more than 35% of these drug candidates are currently in their preclinical stage.
Rnai Therapeutics market size – The “RNAi Therapeutics Market (2nd Edition), 2019-2030: Focus On siRNA, miRNA, shRNA and DNA” report features an extensive study of the current market landscape and future opportunities associated with RNAi therapeutics.
Further, majority (49%) of the RNAi based drug candidates are being administered subcutaneously. Other prominent administration routes include (in the order of popularity) intravenous (22%), intradermal (11%) and intratumoral (9%).
Specifically, 64 companies are developing RNAi therapeutics across all the regions, namely North America, Europe and Asia-Pacific; of these, 20 are start-ups, 17 are mid-sized firms and 26 are large and very large companies. It is worth noting that most of the start-ups in this domain are primarily focused on evaluating drugs in the early stages of development (preclinical / discovery). Some examples of large and very large companies involved in this domain include (in alphabetical order, no selection criteria) Alnylam Pharmaceuticals, bluebird bio, Boehringer Ingelheim, Bristol-Myers Squibb, Nitto Denko Corporation, Pfizer and Roche.
In 2019, the projected market is worth USD 160 million. We expect the overall RNAi therapeutics market to be worth USD 3.9 billion by 2025 and this value is projected to reach USD 9.2 billion by 2030. This represents annualized growth rate of 45% between 2019 and 2030. In the optimistic scenario, we expect the market to be worth USD 4.1 billion by 2025 and USD 9.6 billion by 2030. In the conservative scenario, our projections indicate that the market is likely to be worth USD 3.7 billion by 2025 and USD 8.7 billion by 2030. Additional details of these scenarios are outlined in the appendices.
Presently, the market is dominated by the presence of RNAi therapeutics developed using the siRNA molecule. By 2025, RNAi drug candidate based on shRNA molecule are likely to enter the market. However, in 2030, RNAi therapeutics developed using siRNA molecule are still anticipated to capture the highest market share (99.6%).
Currently, most of RNAi based drugs are being developed for the treatment of genetic disorders (87.1%), followed by those intended for metabolic disorders (7.8%). Further, drug candidates targeting genetic disorders are anticipated to capture the highest share (33.3%) by 2030. This is likely to be followed by RNAi therapeutics intended for the treatment of metabolic disorders (25%) and ophthalmic disorders (23%).
Presently, the intravenous route of administration is preferred by most of the developers. However, by 2025, the market is likely to be dominated by the presence of drug candidates being administered through the subcutaneous route (58%) and in form of eye drops (21%). This trend is unlikely to change in the future as well. In fact, in 2030, RNAi therapeutics administered through the subcutaneous route are likely to capture 62% of the market share, followed by those delivered in form of eye drops (23%).
In 2020, Alnylam Pharmaceuticals is expected to capture a significant share of the market and this trend is unlikely to change in the future as a large number of its lead drug candidates are currently being evaluated in late stages. However, till 2030, Sylentis is likely to capture more than 20% stake in the RNAi therapeutics market.
For more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html
It is worth highlighting that majority of RNAi therapeutics in higher stages of clinical development are being evaluated in North America. In fact, in 2020, RNAi based drugs being developed in North America and Europe capture 93% of the market share. Furthermore, North America is anticipated to capture the highest share (57%) by 2030, followed by Europe (42%). On the other hand, countries in Asia-pacific are expected to capture only 2% of the total market, by 2030.
You may also be interested in the following titles:
- Brain Concussion Market, 2021-2031
- Hunter Syndrome: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031
- Pediatric Brain Tumors: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031
- Neurotrophic Keratitis: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031
- Neuromyelitis Optica Spectrum Disorder (2nd Edition): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Ben Johnson
+1 (415) 800 3415
ben.johnson@rootsanalysis.com
Facebook – https://www.facebook.com/RootsAnalysis
LinkedIn – https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter – https://twitter.com/RootsAnalysis
Medium – https://medium.com/@RootsAnalysis
Pinterest – https://in.pinterest.com/RootsanalysisPin/_saved/
